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0.58–0.65) for minor depression, 0.57 (95% CI 0.54–0.61) 
for mild depression, 0.52 (95%CI 0.49–0.56) for moder-
ate depression, and 0.39 (95% CI 0.35–0.43) for severe 
depression. In comparison with the EQ-5D, the utility 
scores based on the SF-6D were similar for remission (EQ-
5D = 0.70 vs. SF-6D = 0.69), but higher for severe depres-
sion (EQ-5D = 0.39 vs. SF-6D = 0.55).
Conclusions We observed statistically significant differ-
ences in utility scores between depression health states. 
Individuals with less severe depressive symptoms had on 
average statistically significant higher utility scores than 
individuals suffering from more severe depressive symp-
tomatology. In the present study, EQ-5D had a larger range 
of values as compared to SF-6D.
Keywords Utility scores · Quality-of-life · Depression · 
Multilevel analysis · EQ-5D · SF-6D
Abstract 
Objectives Depression is associated with considerable 
impairments in health-related quality-of-life. However, 
the relationship between different health states related to 
depression severity and utility scores is unclear. The aim of 
this study was to evaluate whether utility scores are differ-
ent for various health states related to depression severity.
Methods We gathered individual participant data from ten 
randomized controlled trials evaluating depression treat-
ments. The UK EQ-5D and SF-6D tariffs were used to 
generate utility scores. We defined five health states that 
were proposed from American Psychiatric Association and 
National Institute for Clinical Excellence guidelines: remis-
sion, minor depression, mild depression, moderate depres-
sion, and severe depression. We performed multilevel lin-
ear regression analysis.
Results We included 1629 participants in the analyses. 
The average EQ-5D utility scores for the five health states 
were 0.70 (95% CI 0.67–0.73) for remission, 0.62 (95% CI 
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Introduction
Depression is a common mental disorder with a 12-month 
prevalence of 5.3% and a lifetime prevalence of 13.2% [1]. 
It is expected to rank first in terms of disability-adjusted 
life-years (DALYs) in high-income countries by 2030 
[1–3]. Depression constitutes an enormous societal cost 
due to increased absenteeism, decreased work performance, 
and high healthcare utilization of depressed individuals [4, 
5]. Moreover, it is related to considerable reductions in 
health-related quality-of-life (HRQoL) [6, 7]. Impairments 
in HRQoL are seen in mental, physical, and social func-
tioning and negatively affect various aspects of the individ-
ual’s daily life [8].
HRQoL can be expressed as a utility score that repre-
sents the relative societal desirability of a particular health 
state that is anchored by 0 (death) and 1 (perfect health) [9]. 
Utility scores are most commonly estimated using an indi-
rect method, meaning that participants fill out a HRQoL 
questionnaire and then an algorithm is used to convert the 
participant’s health state into a utility score [10, 11]. These 
utility scores are often used to generate Quality-Adjusted 
Life-Years (QALYs) [10]. A QALY is a measure that com-
bines quality and quantity of life lived and is calculated by 
multiplying the utility score by the amount of time a par-
ticipant spent in a particular health state. Many national 
guidelines for economic evaluations, for example in the 
Netherlands and the United Kingdom, recommend using 
QALYs in economic evaluations because they allow for 
comparisons across different treatments and health prob-
lems [11].
Depression severity can be categorized in different 
health states, namely remission and minor, mild, moder-
ate, and severe depression. The association between health 
states related to depression severity and utility scores is not 
yet well researched. Two studies have examined the rela-
tionship between utility scores and different health states 
[12, 13]. They showed that depression has a considerable 
impact on utility scores, where more severe depression was 
associated with lower utility scores.
However, the aforementioned studies have several limi-
tations. First, participants in both studies received antide-
pressant medication [12, 13]. Consequently, the findings 
may not be generalizable to individuals with depressive 
symptoms receiving no treatment or other types of treat-
ment such as psychotherapy or combined treatments. Sec-
ondly, relatively small sample sizes were used in the analy-
ses (n = 70 and n = 447, respectively) [12, 13]. Thus, these 
two studies could be underpowered to detect small but sta-
tistically significant differences in utility scores between 
health states. Furthermore, one study used the EuroQoL- 5 
Dimensions (EQ-5D) [14] to estimate utility scores and the 
other the Short-Form (SF)- 6 Dimensions [15]. However, it 
has been demonstrated that there are discrepancies between 
utility scores derived from the EQ-5D and the SF-6D lead-
ing to higher EQ-5D utility scores for healthier groups and 
higher SF-6D utility scores for less healthy groups [16, 17].
A recent meta-analysis aimed to pool the utility scores 
from different studies for three depression states (i.e., mild, 
moderate, and severe) [18]. In total, the results from three 
studies were pooled regarding EQ-5D utilities. The authors 
indicated that milder depressive symptoms were related 
to increased utility scores [18]. However, the number of 
included studies was limited and the statistical heteroge-
neity was considerable. Thus, the results may have limited 
generalizability and their validity may not be established.
Given the above, we included a large, representative 
sample of participants with depression, receiving interven-
tions or being in control groups. Subsequently, we aimed 
to establish the utility scores, generated separately from 
EQ-5D and SF-6D tariffs for different health states related 
to depression severity. Secondly, we aimed to compare util-
ity scores between clinically relevant depression health 
states. We hypothesized that the more severe health states 
would be related to lower utility scores and vice versa. The 
final objective was to investigate for potential differences 
between EQ-5D and SF-6D utility scores. We hypothesized 
that EQ-5D utility scores will have a wider range of values 
compared to the SF-6D [16, 17].
Methods
Study selection
We carried out an individual participant data meta-analysis 
to estimate utility scores per predefined health state and to 
compare utility scores between health states. We performed 
a search in PubMed to identify relevant studies, using terms 
indicative for depressive symptoms, treatment for depres-
sion, quality-of-life, and randomized controlled trials. We 
did not aim to conduct a systematic review because this 
was not necessary for answering our research questions.
Two researchers examined the eligibility of the identi-
fied studies (SK and JEB). RCTs were eligible if they (a) 
included participants with a diagnosis of a depressive dis-
order based on a structured clinical interview, or partici-
pants with elevated depressive symptomatology based on a 
standardized measure of depressive symptom severity, (b) 
compared a treatment for depression with a control condi-
tion (i.e., care as usual or a waiting list group), (c) admin-
istered the EQ-5D-3L and/or SF-12 or SF-36 as a measure 
of HRQoL, (d) included a measure of depressive symptom 
severity (e.g., PHQ-9), and (e) were conducted in the Neth-
erlands (to facilitate data sharing).
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Data extraction and preparation
We contacted the authors of RCTs that satisfied our inclu-
sion criteria and asked them permission to access their pri-
mary datasets. The authors signed a data sharing agreement 
that we provided. Data concerning participant registra-
tion number, gender, age, relationship status (not married/
divorced/widowed, or married/living together with a part-
ner), treatment group (intervention or control), education 
level (low, medium, high), comorbidity (study included 
exclusively participants with depression and another 
comorbid condition), and HRQoL and depression sever-
ity scores for all available measurements (i.e., baseline and 
follow-ups) were requested from the authors. All acquired 
data were strictly anonymous and it was not possible to 
track the identity of any of the participants. After receiving 
the primary datasets, we combined them in one database. 
Two researchers extracted the data from the primary data-
sets independently (SK and BvE or DM).
Utility scores were calculated using the UK EQ-5D 
and SF-6D tariffs (there are no Dutch tariffs available for 
SF-6D) [19, 20]. Included studies used different measures 
to monitor depressive symptom severity (Table 1). We used 
cut-off scores obtained from the literature for each of these 
measures to define the participant’s health state. The cut-
off scores and the range of the questionnaires are reported 
in detail in Table 1. In accordance with the American Psy-
chiatric Association (APA) [21] and National Institute for 
Clinical Excellence (NICE) [22] guidelines, we differenti-
ated between five health states: remission (no or minimal 
depressive symptoms and no specific concern for clinical 
depression), minor depression (subthreshold/subclinical 
depression), and mild depression, moderate depression, and 
severe depression (three different severity levels of clinical 
depression).
Statistical analysis
We performed the analyses using the combined data-
base. We used descriptive statistics to describe the demo-
graphic characteristics of the participants. To estimate the 
utility scores for each health state, we used a multilevel 
linear regression model in which we accounted for obser-
vations nested within participants and participants nested 
within studies (i.e., three-level structure). We used the 
default maximum-likelihood approach implemented in 
MLwiN [23]. Separate analyses were carried out for the 
EQ-5D and SF-6D. The utility scores were the depend-
ent variables, and four dummy variables representing the 
five health states were the independent variables. Based 
on the literature, we added the variables comorbidity, 
gender, age, relationship status, randomization group, 
and education level to the model to examine possible 
confounding effects. To determine whether there was 
confounding, we used the ‘rule of thumb’ of 10% change 
in the random coefficients between the model without 
covariates (crude model) and the model with covariates 
(adjusted model) [24, 25]. We also carried out a linear 
regression analysis without taking into account the hier-
archical structure of the data (‘baseline model’). Statisti-
cal significance was set at p < .05.
Sensitivity analysis
We performed two sensitivity analyses. First, we repeated 
the analyses using the Dutch EQ-5D tariffs (there are 
no Dutch tariffs for SF-6D) [26], because we wanted to 
investigate whether our conclusions remain the same 
when using population preference values from different 
countries [27, 28]. In the second sensitivity analysis, we 
included only the baseline measurements from EQ-5D 
and SF-36 to calculate the mean utility scores for each 
health state. The main analyses included all the meas-
urements of the participants (i.e., baseline and follow-
ups) and, even though we controlled for this in the mul-
tilevel analysis, it is possible that it could influence our 
estimates.
Table 1  Cut-off scores 
for health states related to 
depressive symptom severity
CES-D center for epidemiologic studies depression scale, HADS-D hospital anxiety and depression scale, 
IDS-SR inventory of depressive symptomatology self-report; MADRS Montgomery–Åsberg depression rat-
ing scale, PHQ-9 patient health questionnaire
Measures Remission Minor depres-
sive symptoms
Mild depression Moderate 
depression
Severe depression
PHQ-9 [50–52] 0–4 5–9 10–14 15–19 20–27
MADRS [53, 54] 0–8 9–18 19–26 27–34 35–60
CES-D [55–57] 0–15 16–19 20–25 26–30 31–60
IDS-SR [58, 59] 0–13 14–25 26–38 39–48 49–84
HADS-D [60, 61] 0–7 8–13 14–19 20–25 26–52
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Results
Characteristics of included studies
We included ten studies with 1629 participants. All stud-
ies were conducted in the Netherlands and are presented 
in detail in Table 2. Four of them evaluated psychological 
treatments as an intervention (i.e., interpersonal psycho-
therapy, problem solving treatment, and cognitive behav-
ioral therapy), two evaluated collaborative care (i.e., 
combination of general practitioner, psychiatrist, psy-
chotherapist, and depression care manager), two stepped 
care (i.e., watchful waiting, activity scheduling, life 
review and consultation, and general practitioner), one 
disease management (i.e., general practitioner screening 
and consultation), and one medication and care as usual 
(i.e., antidepressants, consultation and information on 
depression). As a comparator, eight studies included care 
as usual and two used waiting list groups. Four studies 
included participants with depression and another comor-
bid condition.
Depression measures included Center for Epidemio-
logic Studies Depression Scale (CES-D, n = 3), Mont-
gomery–Åsberg Depression Rating Scale (MADRS, 
n = 3), Patient Health Questionnaire (PHQ-9, n = 2), 
Inventory of Depressive Symptomatology Self-Report 
(IDS-SR, n = 1), and Hospital Anxiety and Depression 
Scale (HADS-D, n = 1). All studies administered the EQ-
5D-3L and five of them also administered the SF-36.
Table 2  Characteristics of the included studies
CAU care as usual, CBT cognitive behavioral therapy, CES-D center for epidemiologic studies depression scale, HADS-D hospital anxiety and 
depression scale, HRQoL health-related quality-of-life, IDS-SR inventory of depressive symptomatology self-report, MADRS Montgomery–
Åsberg depression rating scale, PHQ-9 patient health questionnaire, PST problem solving treatment, WL Waiting list
a Follow-up in weeks from baseline
First author, year Target group Intervention Control Depression measure HRQoL measure Follow-Upa
Bosmans 2007 [62] Primary care elder par-
ticipants with major 
depression
Interpersonal psycho-
therapy = 69
CAU = 74 MADRS EQ-5D-3L
SF-36
26; 52
Bosmans 2014 [63] Elder participants in 
elderly homes at risk 
for depressive and/or 
anxiety disorders
Stepped care prevention 
program = 93
CAU = 92 CES-D EQ-5D-3L 4; 17; 30; 43
Hermens 2007 [64] Primary care partici-
pants with minor or 
mild major depression
CAU + antidepres-
sants = 85
CAU = 96 MADRS EQ-5D-3L
SF-36
6; 13; 52
Huijbregts 2013 [65] Primary care par-
ticipants with major 
depression
Collaborative care = 61 CAU = 38 PHQ-9 EQ-5D-3L 13; 26; 39; 52
van Marwijk 2008 [66] Primary care par-
ticipants with major 
depression
Program-based disease 
management = 70
CAU = 75 MADRS EQ-5D-3L
SF-36
9; 26; 52
Schreuders 2007 [67] Primary care par-
ticipants with mental 
health problems
PST + CAU = 88 CAU = 87 HADS-D EQ-5D-3L
SF-36
13; 39
Seekles 2011 [68] Primary care par-
ticipants with minor/
major depression and 
anxiety disorder
Stepped care = 60 CAU = 60 IDS EQ-5D-3L 8; 16; 24
van Steenbergen-Wei-
jenburg 2015 [69]
Participants at general 
hospital with chronic 
diseases and major 
depression
Collaborative Care = 42 CAU = 40 PHQ-9 EQ-5D-3L
SF-36
26; 52; 78; 104
van Straten 2007 [70] Self-referred partici-
pants with depression, 
anxiety, or work-
related stress
Web-based PST = 107 WL = 106 CES-D EQ-5D-3L 5; 9
Warmerdam 2010 [71] Self-referred partici-
pants with depressive 
symptoms
Web-based PST = 88; 
Web-based CBT = 88
WL = 87 CES-D EQ-5D-3L 5; 8; 12; 39
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Characteristics of participants
The demographic characteristics of the participants are 
presented in Table 3. From the 1629 participants, 856 had 
been randomized to an intervention group and 773 to a 
control group. Furthermore, 1087 participants were female 
(67%). The mean age was 56 years (SD = 18) and 720 par-
ticipants (49%) were married or lived together with a part-
ner (Table  3). Also, 569 participants (35%) had a lower 
education level (basic education or elementary school), 488 
(31%) had an intermediate education level (high school or 
12 years of education), and 536 (34%) had a higher edu-
cation level (education after high school or university level 
degree).
EQ‑5D utility scores
We included 4979 observations in the analyses. Table  4 
presents the average utility scores from the adjusted model 
based on the EQ-5D and the mean differences between 
the health states. The average utility scores in the adjusted 
model were 0.70 (95% CI 0.67–0.73) for remission, 0.62 
Table 3  Demographic 
characteristics of participants*
Frequencies do not add up to n = 1629 due to missing data
*Presented are frequencies and valid percentages, unless otherwise indicated.
SD standard deviation
Characteristic Intervention 
(n = 856)
Control (n = 773) Total (n = 1629)
Female 588 (69) 499 (65) 1087 (67)
Mean age (SD) 55 (18) 56 (18) 56 (18)
Relationship status
 Unmarried/ divorced/ widowed 379 (49) 383 (54) 762 (51)
 Married/living together 388 (51) 332 (46) 720 (49)
Education level
 Low 284 (34) 285 (38) 569 (35)
 Middle 254 (30) 234 (31) 488 (31)
 High 301 (36) 235 (31) 536 (34)
Table 4  Mean utility scores and mean differences (95% confidence intervals) for different health states of depression
Nobs number of observations
*P < .05; **P < .01; ***P < .001
Reference\comparator Remission Minor depression Mild depression Moderate depression Severe depression
EQ-5D (Nobs = 4979)
Remission 0.70 (0.67 to 0.73) −0.08 (−0.10 to 
− 0.06)***
−0.13 (−0.15 to 
− 0.1.)***
−0.18 (− 0.20 to 
− 0.15)***
−0.34 (−0.37 to − 0.30) 
***
Minor depression X 0.62 (0.58 to 0.65) −0.04 (−0.07 to 
−0.02)***
-0.09 (− 0.12 to 
− 0.07)***
−0.26 (−0.29 to 
− 0.22)***
Mild depression X X 0.57 (0.54 to 0.61) −0.05 (− 0.07 to 
− 0.03)***
−0.21 (−0.25 to 
− 0.18)***
Moderate depression X X X 0.52 (0.49 to 0.56) −0.16 (−0.20 to 
−0.13)***
Severe depression X X X X 0.39 (0.35–0.43)
SF-6D (Nobs = 1726)
Remission 0.69 (0.67–0.71) −0.06 (−0.08 to 
−0.04)***
−0.10 (−0.12 to 
− 0.08)***
−0.13 (− 0.15 to 
− 0.11)***
−0.14 (−0.16 to 
− 0.12)***
Minor depression X 0.63 (0.61 to 0.66) −0.04 (−0.06 to 
0.02)***
−0.07 (− 0.09 to 
− 0.05)***
−0.08 (− 0.10 to 
− 0.6)***
Mild depression X X 0.59 (0.58 to 0.61) −0.03 (−0.05 to 
− 0.01)**
−0.04 (−0.06 to 
− 0.02)***
Moderate depression X X X 0.56 (0.54 to 0.59) −0.01 (−0.03 to 0.00)
Severe depression X X X X 0.55 (0.53 to 0.57)
1654 Qual Life Res (2017) 26:1649–1658
1 3
(95% CI 0.58–0.65) for minor depression, 0.57 (95% CI 
0.54–0.61) for mild depression, 0.52 (95% CI 0.49–0.56) 
for moderate depression, and 0.39 (95%CI 0.35–0.43) for 
severe depression.
The mean utility scores were statistically significantly 
different between all five health states. The largest mean 
difference was found between remission and severe depres-
sion (−0.34, 95% CI −0.37 to −0.30). The smallest mean 
difference was found between minor and mild depression 
(−0.04, 95% CI −0.07 to −0.02). The covariates includ-
ing comorbidity, age, gender, relationship status, rand-
omization group, and education level were included in the 
adjusted model but the random coefficients of health states 
did not change by more than 10% (see Supplementary 
material, Table S1). Thus, we inferred that these covariates 
did not confound our estimations.
SF‑6D utility scores
We used SF-6D utility scores as the dependent variable and 
included 1726 observations (Table  4). The average utility 
scores in the adjusted model were 0.69 (95% CI 0.67–0.71) 
for remission, 0.63 (95% CI 0.61–0.66) for minor depres-
sion, 0.59 (95% CI 0.58–0.62) for mild depression, 0.56 
(95% CI 0.54–0.59) for moderate depression, and 0.55 
(95% CI 0.53–0.57) for severe depression.
The mean differences in utility scores between the health 
states were statistically significant, except for the difference 
between moderate and severe depression (−0.01, 95% CI 
−0.03–0.00). We did not detect any confounding of our 
estimations (see Supplementary material, Table S1).
Differences between EQ‑5D and SF‑6D utility scores
Overall, the mean differences in utility scores between the 
health states were larger for EQ-5D than for SF-6D. The 
SF-6D in comparison with the EQ-5D showed a smaller 
range of utility scores (Table  4). In particular, it gener-
ated slightly lower utility scores for participants in less 
severe health states, and higher scores for more severe 
health states such as severe depression (EQ-5D = 0.39 vs. 
SF-6D = 0.55) (Table 4).
Sensitivity analyses
We calculated the utility scores using the Dutch EQ-5D 
tariffs. The average utility scores for the adjusted model 
were 0.73 (95% CI 0.69–0.77) for remission, 0.63 (95% CI 
0.59–0.67) for minor depression, 0.58 (95% CI 0.54–0.62) 
for mild depression, 0.51 (95% CI 0.47–0.55) for moder-
ate depression, and 0.37 (95%CI 0.33–0.41) for severe 
depression.
The sensitivity analysis using only baseline scores 
for EQ-5D (UK tariffs) included 1453 observations. The 
mean utility scores of the adjusted model were 0.72 (95% 
CI 0.63–0.80) for remission, 0.62 (95% CI 0.55–0.69) 
for minor depression, 0.55 (95% CI 0.47–0.62) for mild 
depression, 0.47 (95% CI 0.40–0.55) for moderate depres-
sion, and 0.30 (95% CI 0.23–0.38) for severe depression.
The sensitivity analysis using only baseline scores for 
SF-6D included 520 observations. The average utility 
scores of the adjusted model were 0.68 (95% CI 0.65–0.72) 
for remission, 0.63 (95% CI 0.60–0.63) for minor depres-
sion, 0.57 (95% CI 0.54–0.60) for mild depression, 0.55 
(95% CI 0.52–0.58) for moderate depression, and 0.54 
(95% CI 0.49–0.58) for severe depression.
Discussion
The present study estimated utility scores derived from 
the EQ-5D and the SF-6D for five health states related to 
depression severity using individual participant data from 
ten clinical trials. The results demonstrated that utility 
scores differed statistically significant between the health 
states, and that less severe health states were associated 
with higher utility scores.
There are some differences between the utility scores 
that we found for each health state and those reported in 
the literature. For instance, the average utility score for 
remission (0.69–0.71) was somewhat lower than those 
reported in other studies (0.72–0.86) [12, 13]. In addi-
tion, the average utility score for severe depression in our 
study (0.39–0.55) was higher as compared to the previous 
findings (0.27–0.30) [12, 13]. These differences may be 
explained by the differences in design and methodology 
between the present and the previous studies. To illustrate, 
one of the previous studies evaluated depression sever-
ity based on physician’s judgment in combination with 
the Clinical Global Impression Improvement Scale (CGI-
I) [13], while in the other study the participants evaluated 
hypothetical health states related to depression severity 
[12]. Furthermore, these studies were conducted in the US 
(using SF-6D) and Sweden (using EQ-5D) and used differ-
ent tariffs to calculate utility scores.
The average utility score for remission found in our 
study was lower than the average utility score of the general 
population (between 0.76 and 0.87) [17, 29, 30]. This find-
ing is in line with the literature, indicating that individu-
als in remission from depression may suffer from residual 
impairments in HRQoL [31, 32]. Thus, evaluating treat-
ment success based on remission of depression symptoms 
alone may be too restrictive. Improvements in HRQoL may 
take longer to occur and should, therefore, be monitored 
after remission of depressive symptoms as well [31, 33].
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There is doubt in the literature regarding the perfor-
mance of EQ-5D and SF-6D in detecting small but impor-
tant changes in utility values [34–36]. Although we showed 
that most of the differences in utility scores between the 
five health states were statistically significant, it is impor-
tant to examine whether the detected differences are also 
clinically relevant [37]. Clinical relevance can be defined 
as the minimum change in an outcome that is perceived by 
the individuals as relevant and beneficial and has a notable 
effect on their daily life [38]. A previous systematic review 
showed that a clinically relevant change in utility score for 
the EQ-5D ranged between 0.01 and 0.14 (mean = 0.07) 
and for the SF-6D between 0.01 and 0.10 (mean = 0.04) 
[39]. Therefore, most of the mean differences in EQ-5D 
and SF-6D utility scores between the health states in our 
study appeared clinically relevant. There was no evidence 
that the differences between minor and mild, and mild and 
moderate depression for EQ-5D utility scores were clini-
cally relevant. Similarly, for SF-6D utility scores, the differ-
ences between mild and moderate, and moderate and severe 
depression did not appear clinically relevant.
Our results are in line with the previous findings indicat-
ing that the EQ-5D generates higher utility scores than the 
SF-6D among healthier participants and lower scores for 
less healthier participants (i.e., severe depression) [17, 40]. 
This discrepancy has been addressed before [36, 41–43] 
and has been attributed to the different scoring algorithms, 
number of possible health states, and the approach through 
which the utility scores are generated [41]. It is, therefore, 
important to consider that utility scores for health states 
related to depression severity are dependent on the measure 
from which they are generated.
The sensitivity analyses that we conducted demonstrated 
the robustness of our results. In particular, when we used 
the Dutch EQ-5D tariffs, the mean utility scores changed 
slightly, as it was expected. Nevertheless, in line with the 
main analyses, participants with more severe depressive 
symptoms had on average lower utility scores. Similarly, 
when we included only the baseline measurements in our 
models, the mean utility scores were in accordance with 
those in the main analyses.
Strengths and limitations
To our knowledge, this is the first study examining the 
relationship between utility scores and health states 
related to depression that includes a large sample size 
providing sufficient statistical power. Furthermore, we 
performed the analyses using multilevel modeling, which 
is considered the most appropriate approach to analyze 
hierarchically structured data and takes into account 
potential differences between the included studies [44]. 
We used utility scores generated from both the EQ-5D-3L 
and the SF-36. Finally, we provided mean utility scores 
for the five health states related to depression severity 
that are recommended by APA and NICE [21, 22].
In model-based economic evaluations, health eco-
nomic models are used to examine the long-term cost-
utility of interventions for depression. Utility scores are 
typically included in these models to calculate QALYs. 
Previous model-based studies populated their models 
with utility scores selected from only a limited set of 
studies [45]. Our study shows some important advan-
tages over previous studies [12, 13] (e.g., large sample 
size, health states based on national guidelines) and our 
findings can be used to populate health economic models 
with more confidence. For instance, we intend to use the 
results of this study to populate a health economic model 
examining the cost-effectiveness of a “blended” (face-to-
face and Internet-based) treatment for depression, which 
is part of the E-COMPARED project funded under the 
Seventh Framework Program [46].
The present study is not without limitations. We used 
different measures of depressive symptom severity to 
define the health states related to depression severity, 
while cut-off scores for depression were based on the 
literature [47]. However, some studies in the literature 
reported different cut-off scores for the same instruments. 
The combination of different measures and the employ-
ment of cut-off scores could potentially lead to over-
lapping health states. Nevertheless, as reflected by the 
clinically relevant and statistically significant mean dif-
ferences in the utility scores, the health states were a reli-
able representation of depressive symptom severity.
We used tariffs generated from a UK population to cal-
culate the utility scores. It is possible that utility scores 
would be slightly different if we would have used stud-
ies and population preference values from other countries 
[27, 28]. However, the sensitivity analyses using Dutch 
tariffs for EQ-5D showed that our findings are robust. 
Similarly, using the EQ-5D-5L, which was recently intro-
duced, may result in different outcomes [48]. Further-
more, the mean age of our sample was somewhat high 
(i.e., 56 years old). Older age can be a factor related to 
lower HRQoL, but we statistically controlled for it with-
out finding any statistically significant associations. 
In addition, comorbidity is very common for patients 
with depression and it may be related to impairments in 
HRQoL [49, 50]. We statistically controlled for comor-
bidity but we did not find any significant relationship. 
Finally, comorbidity and age of participants do not seem 
a threat to the validity of our estimations because the 
mean utility scores were similar or higher than utility 
scores reported for participants with depression in other 
studies.
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Conclusion
We demonstrated that there are statistically signifi-
cant and clinically relevant differences in utility scores 
between the health states. Particularly, individuals with 
less severe depressive symptoms had on average higher 
utility scores than individuals with more severe depres-
sive symptomatology. Considering that individuals in 
remission from depression had on average lower utility 
scores than the general population, it is important to take 
into account HRQoL as an outcome of depression treat-
ments. Differences between EQ-5D and SF-6D utility 
scores, and particularly the larger range of EQ-5D values, 
need to be considered for future economic evaluations 
and health economic models.
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